Identification of the novel HLA-B*15:270 allele by Sanger dideoxy nucleotide sequencing.

HLA-B*15:270 differs from HLA-B*15:12:01 by one nucleotide substitution at position 679 in exon 4.

The novel HLA-A*02:405 allele characterized by sequencing-based typing.

HLA-A*02:405 differs from HLA-A*02:06:01:01 by one nucleotide substitution in codon 161 in exon 3.

The novel HLA-A*02:404 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual.

HLA-A*02:404 differs from HLA-A*02:06:01:01 by one nucleotide substitution in codon 116 in exon 3.

A novel HLA allele, HLA-B*07:248, detected in a Chinese hematopoietic stem cell donor and platelet donor.

HLA-B*07:248 has one nucleotide change from HLA-B*07:18:01 where Tyrosine (Y) is changed to Serine (S).

Discovery of the novel HLA allele, HLA-DRB1*15:123, in a hematopoietic stem cell donor from China.

HLA-DRB1*15:123 has one nucleotide change from HLA-DRB1*15:01:01:01 where Threonine (90) is changed to Isoleucine.

A novel HLA allele, HLA-A*32:74, detected by sequencing in a Chinese individual.

HLA-A*32:74 has one nucleotide change from HLA-A*32:01:01:01 where alanine (211) is changed to glutamate.

Identification of a novel HLA-A allele, HLA-A*31:97, by sequence-based typing.

HLA-A*31:97 differs by three nucleotide and two amino acid changes from HLA-A*31:01:02:01.

Discovery of the novel HLA-B*52:49N allele in a Chinese individual.

HLA-B*52:49N has one nucleotide change from HLA-B*52:01:01:01 where 601G (GAG) is changed to T(TAG).

Involvement of microRNA-155 in the mechanism of electroacupuncture treatment effects on experimental autoimmune encephalomyelitis.

Multiple sclerosis (MS) is a neurodegenerative and demyelinating autoimmune disease mediated by autoreactive T cells that affects the central nervous system (CNS). Electroacupuncture (EA) has emerged as an alternative or supplemental treatment for MS, but the mechanism by which EA may alleviate MS symptoms is unresolved. Here, we examined the effects of EA at the Zusanli (ST36) acupoint on mice with experimental autoimmune encephalomyelitis (EAE), the predominant animal model of MS.

Peptide-based therapeutic cancer vaccine: Current trends in clinical application.

The peptide-based therapeutic cancer vaccines have attracted enormous attention in recent years as one of the effective treatments of tumour immunotherapy. Most of peptide-based vaccines are based on epitope peptides stimulating CD8 T cells or CD4 T helper cells to target tumour-associated antigens (TAAs) or tumour-specific antigens (TSAs). Some adjuvants and nanomaterials have been exploited to optimize the efficiency of immune response of the epitope peptide to improve its clinical application.

The Impacts of Non-coding RNAs and N-Methyladenosine on Cancer: Past, Present and Future.

N6-methyladenosine (mA) modifications control multifaceted RNA metabolism and are one of the most extensively distributed modifications on the human transcriptome, including non-coding RNAs (ncRNAs). Previous concepts of ncRNAs as "junk" transcriptional products have evolved to the concept that ncRNAs are functional regulatory molecules that determine specific biological processes and cell fates. The dysregulation of mA modifications and ncRNAs have been implicated in the development of human carcinogenesis.

Two novel FUT1 alleles that cause para-Bombay phenotype in a Chinese individual.

Background: Bombay and para-Bombay phenotypes, which arise from gene mutations of α-1,2-fucosyltransferase FUT1, are very rare in Chinese population. A para-Bombay phenotype Chinese individual with two novel FUT1 mutations was reported here.

Study Design And Methods: The peripheral blood and saliva samples of the proband and her family members were collected after informed consent.

A novel allele arising from c.912C>A mutation in the α-1,3-N-acetylgalactosaminyltransferase gene in a Chinese individual.

Background: The A phenotype, which arises from mutations of the α-1,3-N-acetylgalactosaminyltransferase gene, is rare in the Chinese population. The present study focuses on a novel mutation with the A phenotype in a Chinese individual.

Study Design And Methods: The sample with ABO blood group discrepancy was analyzed by serologic techniques.

Identification of HLA-A*31:73 in a platelet donor from China by sequence-based typing.

HLA-A*31:73 has one nucleotide change from HLA-A*31:01:02:01 where Serine (71) is changed to Alanine.

Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals.

The global Coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has affected more than eight million people. There is an urgent need to investigate how the adaptive immunity is established in COVID-19 patients. In this study, we profiled adaptive immune cells of PBMCs from recovered COVID-19 patients with varying disease severity using single-cell RNA and TCR/BCR V(D)J sequencing.

A novel HLA-A allele, HLA-A*31:72, detected in a Chinese hematopoietic stem cell donor and platelet donor.

HLA-A*31:72 has one nucleotide change from HLA-A*31:01:02:01, where histidine (188) is changed to arginine.

HLA-A*02:411 identified in a platelet donor from China.

HLA-A*02:411 differs from HLA-A*02:01:01:01 at nucleotides 770 and 771, where Threonine (T) replaces Isoleucine (I) at residue 233.